GlassScriptPhysician profile
Dong Ma
NPI 1598212946
$1,989.03
in general payments reported to CMS, 2019-2025
34 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $438 · 2022: $110 · 2023: $394 · 2024: $772 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.17 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $479.94 | 2021-2025 | |
| Janssen Biotech, INC. | $147.55 | 2021-2025 | Carvykti, Tecvayli |
| Seagen INC. | $140.59 | 2021-2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $98.34 | 2024-2025 | Tagrisso, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $92.15 | 2024-2025 | Keytruda, Lynparza |
| Celgene Corporation | $89.27 | 2021-2024 | Reblozyl |
| Incyte Corporation | $84.47 | 2023-2025 | Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $81.24 | 2023-2024 | Ninlaro, Fruzaqla |
| Daiichi Sankyo INC. | $64.98 | 2021-2023 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $61.67 | 2024 | |
| Amgen INC. | $56.82 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Ipsen Biopharmaceuticals, INC | $54.98 | 2023 | Tazverik |
| Glaxosmithkline, LLC. | $48.98 | 2024 | Zejula, Jemperli |
| Abbvie INC. | $47.22 | 2025 | |
| Global Blood Therapeutics, INC. | $39.19 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Menarini Silicon Biosystems, INC. | $33.28 | 2024 | |
| Blueprint Medicines Corporation | $32.70 | 2024 | Ayvakit |
| Pharmaessentia USA Corporation | $30.38 | 2023-2024 | Besremi |
| Rigel Pharmaceuticals, INC. | $28.84 | 2024 | Tavalisse, Rezlidhia |
| Organon LLC | $24.49 | 2023 | Ontruzant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.16 | 2021 | |
| Novocure INC. | $23.93 | 2024 | Optune |
| Genmab U.S., INC. | $21.33 | 2023 | Epkinly |
| Eisai INC. | $20.74 | 2025 | |
| Genentech USA, INC. | $20.52 | 2024 | Phesgo, Alecensa, Itovebi |
| Mirati Therapeutics, INC. | $19.50 | 2024 | Krazati |
| Array Biopharma INC | $18.50 | 2023 | Mektovi, Xalkori, Lorbrena |
| Puma Biotechnology, INC. | $18.08 | 2025 | |
| Jazz Pharmaceuticals INC. | $16.55 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.17 | 2021 | |
| Lilly USA, LLC | $14.01 | 2025 | Jaypirca, Verzenio |
| Sobi, INC | $13.60 | 2021 | |
| Dova Pharmaceuticals | $13.45 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $13.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dong Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.